

38. Geary J, Sasieni P, Houlston R, et al. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). *Fam Cancer* 2008; 7(2): 163-72.
39. Goecke T, Schulmann K, Engel C, et al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. *J Clin Oncol* 2006; 24(26): 4285-92.
40. Koomstra JJ, Kleibeuker JH, Vasen HF. Small-bowel cancer in Lynch syndrome: is it time for surveillance? *Lancet Oncol* 2008; 9(9): 901-5.
41. Schwartz GD, Barkin JS. Small-bowel tumors detected by wireless capsule endoscopy. *Dig Dis Sci* 2007; 52(4): 1026-30.
42. Baichi MM, Arifuddin RM, Mantry PS. Metachronous small bowel adenocarcinomas detected by capsule endoscopy in a patient with hereditary nonpolyposis colorectal cancer. *Dig Dis Sci* 2007; 52(4): 1134-6.
43. Marmo R, Rotondano G, Riccio G, et al. Small-bowel adenocarcinoma diagnosed via capsule endoscopy in a patient found to have hereditary nonpolyposis colorectal cancer. *Gastrointest Endosc* 2007; 65(3): 524-5.
44. Cheon JH, Kim YS, Lee IS, et al. Can we predict spontaneous capsule passage after retention? A nationwide study to evaluate the incidence and clinical outcomes of capsule retention. *Endoscopy* 2007; 39(12): 1046-52.
45. Yamamoto H, Sekine Y, Sato Y, et al. Total enteroscopy with a nonsurgical steerable double-balloon method. *Gastrointest Endosc* 2001; 53(2): 216-20.
46. Yamamoto H, Kita H, Sunada K, et al. Clinical outcomes of double-balloon endoscopy for the diagnosis and treatment of small-intestinal diseases. *Clin Gastroenterol Hepatol* 2004; 2(11): 1010-6.
47. Lynch HT, Voorhees GJ, Lanspa SJ, et al. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. *Br J Cancer* 1985; 52(2): 271-3.
48. Mecklin JP, Järvinen HJ, Virolainen M. The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma. *Cancer* 1992; 69(5): 1112-4.
49. Brand RE, Lerch MM, Rubinstein WS, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. *Gut* 2007; 56(10): 1460-9.
50. Ardengh JC, Coelho N, Osvaldt AB. [Early pancreatic cancer: can the methods currently available identify this disease?]. *Arq Gastroenterol* 2008; 45(2): 169-77.
51. Lynch HT, Fusaro RM, Lynch JF, et al. Pancreatic cancer and the FAMMM syndrome. *Fam Cancer* 2008; 7(1): 103-12.
52. Rouprêt M, Yates DR, Comperat E, et al. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. *Eur Urol* 2008; 54(6): 1226-36.
53. Sijmons RH, Kiemeneij LA, Witjes JA, et al. Vasen HF. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. *J Urol* 1998; 160(2): 466-70.
54. Myrthøj T, Andersen MB, Bernstein I. Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. *Fam Cancer* 2008; 7(4): 303-7.
55. Lodde M, Mian C, Wiener H, et al. Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report. *Urology* 2001; 58(3): 362-6.
56. Chen AA, Grasso M. Is there a role for FISH in the management and surveillance of patients with upper tract transitional-cell carcinoma? *J Endourol* 2008; 22(6): 1371-4.
57. Ho CL, Tzai TS, Chen JC, et al. The molecular signature for urothelial carcinoma of the upper urinary tract. *J Urol* 2008; 179(3): 1155-9.
58. Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. *Cancer* 2006; 107(9): 2173-9.
59. South CD, Hampel H, Comeras I, et al. The frequency of Muir-Torre syndrome among Lynch syndrome families. *J Natl Cancer Inst* 2008; 100(4): 277-81.
60. Murphy HR, Armstrong R, Cairns D, et al. Greenhalgh KL. Muir-Torre Syndrome: expanding the genotype and phenotype - a further family with a MSH6 mutation. *Fam Cancer* 2008; 7(3): 255-7.
61. Dores GM, Curtis RE, Toro JR, et al. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. *Cancer* 2008; 113(12): 3372-81.
62. Vasen HF, Sanders EA, Taal BG, et al. The risk of brain tumours in hereditary non-polyposis colorectal cancer (HNPCC). *Int J Cancer* 1996; 65(4): 422-5.
63. Gylling AH, Nieminen TT, Abdel-Rahman WM, et al. Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. *Carcinogenesis* 2008; 29(7): 1351-9.
64. de Jong AE, Hendriks YM, Kleibeuker JH, et al. Decrease in mortality in Lynch syndrome families because of surveillance. *Gastroenterology* 2006; 130(3): 665-71.
65. Ponti G, Losi L, Pellacani G, et al. Malignant melanoma in patients with hereditary nonpolyposis colorectal cancer. *Br J Dermatol* 2008; 159(1): 162-8.
66. Sijmons R, Hofstra R, Hollema H, et al. Inclusion of malignant fibrous histiocytoma in the tumour spectrum associated with hereditary non-polyposis colorectal cancer. *Genes Chromosomes Cancer* 2000; 29(4): 353-5.
67. Stulp RP, Herkert JC, Karrenbeld A, et al. Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum. *Hered Cancer Clin Pract* 2008; 6(1): 15-21.
68. Soravia C, van der Klift H, Bründler MA, et al. Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum. *Am J Med Genet A* 2003; 121A(2): 159-62.
69. Akoum R, Ghaoui A, Brihi E, et al. Early-onset breast cancer in a Lebanese family with Lynch syndrome due to MSH2 gene mutation. *Hered Cancer Clin Pract* 2009; 7(1): 10.
70. Pineda M, Castellsagué E, Musulén E, et al. Non-Hodgkin lymphoma related to hereditary nonpolyposis colorectal cancer in a patient with a novel heterozygous complex deletion in the MSH2 gene. *Genes Chromosomes Cancer* 2008; 47(4): 326-3.
71. Nilbert M, Timshel S, Bernstein I, et al. Role for genetic anticipation in Lynch syndrome. *J Clin Oncol* 2001; 27(3): 360-4.